UPDATE: Wunderlich Securities Reiterates Buy Rating, Raises PT on DexCom

In a report published Monday, Wunderlich Securities reiterated its Buy rating on DexCom

, and raised its price target from $15.00 to $18.00. Wunderlich Securities noted, “We are raising our price target on DexCom (DXCM) to $18 per share from $15, reflecting the strong, initial success of the G4 Platinum CGM and additional catalysts on the horizon in 2013. DXCM pre-announced very strong Q4 product revenues last week, and offered solid guidance for 2013. Strong patient acceptance of G4 will drive results, which could leave our 2013 estimates conservative. In addition, FDA approval for pediatric patients and approval of the integrated Animas (JNJ-NR) pump/CGM serve as additional catalysts on the horizon (not built into our current estimates). DXCM is well positioned for strong growth in 2013 and beyond, and we continue to view the company as one of the most attractive acquisition targets in our coverage.” DexCom closed on Friday at $14.82.